An October 15 oversight announcement follows a senator’s request for an investigation, federal charges against two researchers, and allegations that laboratory access continued after an airport detention.
The Department of Health and Human Services Office of Inspector General has opened a review of employee vetting at the National Institutes of Health’s Rocky Mountain Laboratories in Hamilton, Montana, placing the laboratory’s personnel-security practices under federal scrutiny months after a U.S. senator called for an investigation into alleged misconduct involving researchers who handle dangerous pathogens.
The review, announced October 15 under project number OEI-01-26-00560, will examine NIH’s general personnel-vetting procedures for laboratory employees with access to high-risk pathogens, along with the screening of scientific personnel who may work directly with those materials.
The announcement offers little explanation for the review beyond acknowledging that members of Congress have raised concerns about employee vetting.
But a reconstruction of the congressional record identifies a much more substantial history behind those concerns: a federal criminal investigation involving two NIH researchers, whistleblower allegations concerning access to high-containment laboratory facilities, earlier warnings about biological-material shipments, and a formal congressional request for independent oversight.
The central question is no longer simply whether NIH screens its employees before granting access to sensitive research facilities. It is whether the agency’s personnel-security procedures adequately address circumstances in which researchers already entrusted with dangerous biological materials become subjects of serious misconduct allegations or federal investigations.
A Congressional Request Months Before the Review
On May 26, 2026, Montana Republican Senator Tim Sheehy wrote to HHS Inspector General T. March Bell, requesting an investigation into Rocky Mountain Laboratories’ safety, security, and personnel practices.
Sheehy’s letter followed public reporting about a whistleblower complaint alleging misconduct involving laboratory personnel, along with two reported incidents involving possible exposure to Crimean-Congo hemorrhagic fever virus.
The senator specifically requested an examination of employee background checks, personnel oversight, security clearances and other screening processes for individuals handling high-risk pathogens or accessing sensitive facilities.
He also requested a review of NIH procedures governing employees under investigation, including decisions concerning their employment status, facility access, and coordination with law enforcement.
Those requests closely resemble the objectives of the OIG study announced October 15. The publicly available announcement does not explicitly state that Sheehy’s letter initiated the project, or establish whether the OIG intends to examine every incident identified in his correspondence.
The Airport Incident That Preceded the Criminal Charges
The controversy centers partly on a January 25, 2026, encounter at Detroit Metropolitan Airport involving NIH researchers Vincent Munster and Claude Kwe, who were returning from the Republic of Congo. According to a June 2 announcement by the U.S. Attorney’s Office for the Eastern District of Michigan, the two scientists were carrying a large case containing 113 vials packed in Styrofoam coolers.
Federal prosecutors alleged that the researchers falsely represented the case’s contents as diagnostic and testing equipment. Of the first 20 vials tested by the FBI, 17 contained deactivated mpox virus, one contained chickenpox virus, and two contained human DNA, according to the Justice Department.
Munster, identified by prosecutors as chief of the Virus Ecology Section at Rocky Mountain Laboratories, and Kwe, a research fellow in that section, were charged with conspiracy to smuggle biological material into the United States and making false statements to federal law enforcement. The criminal complaint describes allegations, not judicial findings of guilt. Both defendants are presumed innocent unless proven guilty.
The identification of deactivated mpox material is important. The government’s announcement did not establish that the seized mpox samples contained infectious virus, and the laboratory-vetting investigation should not be interpreted as evidence that infectious mpox was released or mishandled at the Montana facility.
The Justice Department identified the HHS Office of Inspector General as one of the agencies participating in the criminal investigation. How that work relates, if at all, to the newly announced evaluation remains unanswered.
The Unresolved Question of Laboratory Access
Perhaps the most consequential allegation in Sheehy’s May correspondence concerns what happened immediately after the researchers’ January airport detention.
The senator cited a whistleblower complaint alleging that Munster and associates were permitted to enter Rocky Mountain Laboratories on January 26, including access to its high-containment Biosafety Level 4 building and office spaces. According to the complaint as reproduced in Sheehy’s letter, access restrictions were imposed on January 27, two days after the airport encounter. The whistleblower also alleged that an associate subsequently regained facility access.
Those claims have not been independently substantiated by Bureaucracy Times. Detention or investigation does not automatically establish that an employee presents a security risk, nor does it necessarily trigger immediate revocation of every facility credential. Decisions may depend on what NIH knew, when it received that information, the employee’s specific access authorization, and applicable security procedures.
If NIH officials were aware of a federal investigation involving the unauthorized transportation of biological materials, what procedures governed continued access to laboratories handling high-risk pathogens? Who was responsible for evaluating the information? Was a security reassessment required? And what records document the timing and justification of restrictions? The OIG announcement does not answer those questions.
Earlier Warnings About Biological Shipments
On June 5, the Senate Homeland Security and Governmental Affairs Committee released a summary of documents describing earlier concerns about handling and shipment of biological materials associated with NIH research.
Among the records described was a December 2021 exchange in which Munster reportedly proposed arranging an international shipment of the Omicron coronavirus variant without using NIH’s established shipping process. According to the committee, an NIH official warned that bypassing those procedures could attract public and congressional scrutiny and noted that Rocky Mountain Laboratories lacked approved shipping procedures on file.
The committee also identified records concerning incorrectly labeled shipments, missing documentation, and biological samples reportedly lost in transit. Those committee-characterized findings raise questions about whether NIH had previously identified procedural weaknesses and implemented corrective measures. They do not establish that earlier shipping issues resulted from failures in employee background screening. Shipping compliance, biosafety, and personnel security are distinct oversight responsibilities.
Two Reported Laboratory Exposure Incidents
Sheehy’s letter identified two reported incidents involving possible exposure to Crimean-Congo hemorrhagic fever virus. The first occurred in November 2025, when an animal bite reportedly breached a laboratory worker’s protective equipment. The employee subsequently underwent monitoring at a specialized medical facility. The second occurred in February 2026, when a laboratory worker handling mice reportedly experienced a breach in protective equipment.
The senator requested that the inspector general examine both incidents, including relevant biosafety procedures and NIH’s response. These events concern laboratory safety rather than necessarily indicating deficiencies in employee vetting. The newly announced OIG project is narrower than the full range of issues in Sheehy’s letter, and its description does not establish that the exposure incidents will be examined.
What the Inspector General Will Examine
The October 15 announcement identifies two principal areas: NIH’s general personnel-vetting process for Rocky Mountain Laboratories staff with access to high-risk pathogens, and the vetting of scientific personnel who may work directly with those pathogens.
Federal laboratories operate under overlapping security and safety requirements. General federal employment background investigations are not necessarily equivalent to specialized access screening for particular biological agents. Applicable requirements depend on position, duties, materials, and regulatory coverage.
An evaluation may need to consider not only whether background checks were completed, but how access decisions are documented, monitored, reassessed, and modified when new information becomes available. The announcement does not identify employees to be examined, disclose methodology, provide a completion date, or announce a finding of wrongdoing.
What Remains Unanswered
The congressional paper trail establishes that concerns about Rocky Mountain Laboratories’ personnel practices were raised formally with HHS OIG months before the new project appeared on its public work plan. Unresolved questions include whether Sheehy’s letter directly initiated the review, whether other congressional communications contributed, and whether the evaluation will examine the January 2026 access allegations.
A general procedural review could determine whether NIH has appropriate vetting policies without resolving whether those policies were followed in particular cases. An examination of actual access-control decisions could establish what NIH officials knew, when they knew it, and whether their responses complied with applicable requirements.
Bureaucracy Times is seeking clarification from HHS OIG regarding the origins and scope of project OEI-01-26-00560, including whether the review encompasses allegations concerning laboratory access following the January airport detention.
For now, the announcement confirms an active examination of personnel vetting at one of NIH’s high-containment research facilities. The congressional record explains why that examination matters. The remaining question is whether the review will address only the rules governing access to dangerous pathogens, or also the decisions made when those rules were tested.
